Official websites use. Share sensitive information only on official, secure websites. Corresponding author. Lower urinary tract symptoms due to benign prostatic hyperplasia constitute a substantial burden, affecting the quality of life of those affected by this condition. While watchful waiting and medical management using a wide array of pharmaceuticals can be effective, surgery has been one of the most definite solutions for those highly affected by this condition.
Transurethral resection of the prostate TURP is the gold standard surgical procedure, but other alternatives using laser HoLEP and ThuLEP and robotic water jets Aquablation are emerging treatments aimed at reducing postoperative morbidity. Minimally invasive procedures conducted in outpatient settings and under local anesthesia or sedation are increasingly being used, especially in those patients with high surgical risk due to comorbidities.
The evidence supporting these treatments is growing, but some uncertainties remain as to what is the magnitude of their advantages and disadvantages compared to TURP.
Innovations in the technologies involved in these new procedures may improve their profile for effectiveness and safety. Moreover, new devices are being investigated for marketing approval. Keywords: Benign prostatic hyperplasia, Evidence-based practice, Minimally invasive surgical procedures. Benign prostatic hyperplasia BPH is a noncancerous enlargement of the prostate gland due to androgenic stimulus exerted by dihydrotestosterone, a metabolite derived from testosterone by the action of the enzyme 5-alpha reductase.
Patients may present with obstructive or irritative symptoms. The natural history of BPH shows that the progression of symptoms is very slow, and serious complications are infrequent. Watchful waiting and lifestyle modifications may be warranted in those with mild symptoms. Physical activity could reduce the symptoms of prostatism, so the recommendation to exercise regularly could be part of this management strategy.
